The five-year grant is part of The Howard Hughes Medical Institute's Driving Change initiative, which focuses on breaking down barriers in STEM fields at research universities. Photo via Rice University

Rice University was recently granted $2.5 million to develop programs that make STEM degrees more accessible to students of all walks of life.

The five-year grant is part of The Howard Hughes Medical Institute's Driving Change initiative, which focuses on breaking down barriers in STEM fields at research universities.

Rice is one of six universities to receive the grant this year. According to a statement from Rice, this year's winners were named for making "culture change efforts" within the universities.

“Rice has laid the groundwork for student success, and this funding will allow us to teach math courses in an accessible way that is inclusive to all students and promotes equity in STEM," Amy Dittmar, Howard R. Hughes Provost and executive vice president for academic affairs, says in a statement. "Students who are underrepresented, first-generation college students, Pell grant recipients, women and athletes should have the same opportunities for success as everyone else.”

Other universities in the 2023 cohort include:

  • The University of California, Los Angeles
  • Illinois State University
  • The University of Massachusetts, Amherst
  • Rice University
  • Rutgers University – Camden
  • The University of Vermont

The first group of six universities awarded a Driving Change grant were named last year. Awardees are also part of the HHMI Driving Change Learning Community of 38 institutions that aim to create more inclusive environments.

“Each of this year’s grantee institutions has demonstrated their dedication to carrying out critical, intensive work for the betterment of the wider world of STEM and STEM education,” Sarah Simmons, HHMI program lead for Driving Change, says in a statement. “Part of this work includes a thorough self-study to ensure that each institution identifies its own unique needs. We are honored to be a part of a community with so many change-makers who are driven by the goal of making science and science education accessible to everyone.”

The grant was secured by Rice team members Janet Braam, Margaret Beier, Alex Byrd, Liz Eich, Dereth Phillips, Caroline Quenemoen, Renata Ramos, Matt Taylor and Tony Varilly Alvarado.

Earlier this fall, Rice also announced the Liu Idea Lab for Innovation and Entrepreneurship, or Lilie, which recruited 11 entrepreneurs to the council with Houston ties to support “promising entrepreneurial programs for students, research staff and faculty.” Each has agreed to donate time and money to the university’s entrepreneurship programs.

That same month, Rice teamed up with Houston Methodist to open the new Center for Human Performance.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Nominations are now open for the 2025 Houston Innovation Awards

Calling All Innovators

Calling all Houston innovators: The Houston Innovation Awards return this fall to celebrate the best and brightest in the Houston innovation ecosystem right now.

Presented by InnovationMap, the fifth annual Houston Innovation Awards will take place November 5 at TMC Helix Park.

The awards program will honor the top startups and innovators in Houston across 10 categories, and we're asking you to nominate the most deserving Houston innovators and innovative companies today.

This year's categories are:

  • Minority-founded Business, honoring an innovative startup founded or co-founded by BIPOC or LGBTQ+ representation.
  • Female-founded Business, honoring an innovative startup founded or co-founded by a woman.
  • Energy Transition Business, honoring an innovative startup providing a solution within renewables, climatetech, clean energy, alternative materials, circular economy, and beyond.
  • Health Tech Business, honoring an innovative startup within the health and medical technology sectors.
  • Deep Tech Business, honoring an innovative startup providing technology solutions based on substantial scientific or engineering challenges, including those in the AI, robotics, and space sectors.
  • Startup of the Year (People's Choice), honoring a startup celebrating a recent milestone or success. The winner will be selected by the community via an interactive voting experience.
  • Scaleup of the Year, honoring an innovative later-stage startup that's recently reached a significant milestone in company growth.
  • Incubator/Accelerator of the Year, honoring a local incubator or accelerator that is championing and fueling the growth of Houston startups.
  • Mentor of the Year, honoring an individual who dedicates their time and expertise to guide and support budding entrepreneurs.
  • Trailblazer, honoring an innovator who's made a lasting impact on the Houston innovation community.

Nominations may be made on behalf of yourself, your organization, and other leaders in the local innovation scene. The nomination period closes on August 31, so don't delay — nominate today at this link, or fill out the embedded form below.

Our panel of esteemed judges will review the nominations, and determine the finalists and winners. Finalists will be unveiled on September 30, and the 2025 Houston Innovation Awards winners will be announced live at our event on November 5.

Tickets will go on sale this fall. Stay tuned for that announcement, as well as more fanfare leading up to the 2025 Houston Innovation Awards.

Nominate now:

Interested in Innovation Awards sponsorship opportunities? Please contact sales@innovationmap.com.

MD Anderson launches $10M collaboration to advance personalized cancer treatment tech

fighting cancer

The University of Texas MD Anderson Cancer Center and Japan’s TOPPAN Holdings Inc. have announced a strategic collaboration to co-develop TOPPAN Holdings’ 3D cell culture, or organoid, technology known as invivoid.

The technology will be used as a tool for personalized cancer treatments and drug screening efforts, according to a release from MD Anderson. TOPPAN has committed $10 million over five years to advance the joint research activities.

“The strategic alliance with MD Anderson paves a promising path toward personalized cancer medicine," Hiroshi Asada, head of the Business Innovation Center at TOPPAN Holdings, said in a news release.

Invivoid is capable of establishing organoid models directly from patient biopsies or other tissues in a way that is faster and more efficient. Researchers may be able to test a variety of potential treatments in the laboratory to understand which approach may work best for the patient, if validated clinically.

“Organoids allow us to model the three-dimensional complexity of human cancers in the lab, thus allowing us to engineer a powerful translational engine—one that could not only predict how patients will respond to therapy before treatment begins but also could help to reimagine how we discover and validate next-generation therapies," Dr. Donna Hansel, division head of pathology and laboratory medicine at MD Anderson, added in the news release. “Through this collaboration, we hope to make meaningful progress in modeling cancer biology for therapeutic innovation.”

The collaboration will build upon preclinical research previously conducted by MD Anderson and TOPPAN. The organizations will work collaboratively to obtain College of American Pathologists (CAP) and Clinical Laboratory Improvement Amendments (CLIA) certifications for the technology, which demonstrate a commitment to high-quality patient care. Once the certifications are obtained, they plan to conduct observational clinical studies and then prospective clinical studies.

“We believe our proprietary invivoid 3D cell culture technology, by enabling the rapid establishment of organoid models directly from patient biopsies, has strong potential to help identify more effective treatment options and reduce the likelihood of unnecessary therapies,” Asada added in the release. “Through collaboration on CAP/CLIA certification and clinical validation, we aim to bring this innovation closer to real-world patient care and contribute meaningfully to the advancement of cancer medicine."